Genomic instability in TP53-mutated breast cancer cells treated with etoposide and doxorubicin.

被引：0
|
作者：
De Vos, ML [1 ]
Weber, BL [1 ]
机构：
[1] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA
来源：
AMERICAN JOURNAL OF HUMAN GENETICS | 2003年 / 73卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
330
引用
收藏
页码：226 / 226
页数：1
相关论文
共 50 条
  • [41] Radioresistance of KRAS/TP53-mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo
    Gurtner, Kristin
    Kryzmien, Zofia
    Koi, Lydia
    Wang, Meng
    Benes, Cyril H.
    Hering, Sandra
    Willers, Henning
    Baumann, Michael
    Krause, Mechthild
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (02) : 472 - 477
  • [42] Nuclear expression of Y box binding-1 is important for resistance to chemotherapy including gemcitabine in TP53-mutated bladder cancer
    Yamashita, Takahisa
    Higashi, Morihiro
    Momose, Shuji
    Morozumi, Makoto
    Tamaru, Jun-Ichi
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2017, 51 (02) : 579 - 586
  • [43] Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF
    Andersson, J
    Larsson, L
    Klaar, S
    Holmberg, L
    Nilsson, J
    Inganäs, M
    Carlsson, G
    Öhd, J
    Rudenstam, CM
    Gustavsson, B
    Bergh, J
    ANNALS OF ONCOLOGY, 2005, 16 (05) : 743 - 748
  • [44] Toxicogenomic activity of gemcitabine in two TP53-mutated bladder cancer cell lines: special focus on cell cycle-related genes
    da Silva, Glenda Nicioli
    de Camargo, Elaine Aparecida
    Favero Salvadori, Daisy Maria
    MOLECULAR BIOLOGY REPORTS, 2012, 39 (12) : 10373 - 10382
  • [45] Breast-cancer stromal cells with TP53 mutations
    Campbell, Ian G.
    Qiu, Wen
    Polyak, Kornelia
    Haviv, Izhak
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (15): : 1634 - 1635
  • [46] Loss of Arp2/3 activity promotes anchorage independent growth in KRAS;TP53-mutated human bronchial epithelial cells
    Li, Chennan
    Kasinski, Andrea L.
    CANCER RESEARCH, 2022, 82 (12)
  • [47] Toxicogenomic activity of gemcitabine in two TP53-mutated bladder cancer cell lines: special focus on cell cycle-related genes
    Glenda Nicioli da Silva
    Elaine Aparecida de Camargo
    Daisy Maria Favero Salvadori
    Molecular Biology Reports, 2012, 39 : 10373 - 10382
  • [48] Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes
    Kim, Ji-Yeon
    Lee, Eunjin
    Park, Kyunghee
    Park, Woong-Yang
    Jung, Hae Hyun
    Ahn, Jin Seok
    Im, Young-Hyuck
    Park, Yeon Hee
    ONCOTARGET, 2017, 8 (17) : 27997 - 28007
  • [49] Hedgehog signaling negatively co-regulates BH3-only protein Noxa and TAp73 in TP53-mutated cells
    Meister, Michael Torsten
    Boedicker, Cathinka
    Klingebiel, Thomas
    Fulda, Simone
    CANCER LETTERS, 2018, 429 : 19 - 28
  • [50] Sp1 regulates Raf/MEK/ERK-induced p21CIP1 transcription in TP53-mutated cancer
    Karkhanis, Mansi
    Park, Jong-In
    CELLULAR SIGNALLING, 2015, 27 (03) : 479 - 486
12345